Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

133.21 +2.35 (+1.80%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

76 77 Next >

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

November 03, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Inc (NASDAQ:GILD): A Dividend Stock with a Secure Payout and Strong Fundamentals ↗

November 03, 2025

Gilead Sciences (GILD) offers a 2.64% dividend yield with a very low payout ratio, strong profitability, and a debt-free balance sheet, making it a compelling dividend stock.

Via Chartmill

Amgen Earnings: What To Look For From AMGN

November 02, 2025

Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings this Tuesday after market close. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings

November 01, 2025

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results this Monday after the bell. Here’s what to expect.

Via StockStory

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Gilead Stock Ignites Retail-Trader Frenzy As Trodelvy Cuts Breast Cancer Progression Risk By 38% In Phase 3 Trial ↗

October 20, 2025

Via Stocktwits

Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect

November 01, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know.

Via StockStory

Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout

October 31, 2025

Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant...

Via MarketMinute

Topics Intellectual Property

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026 ↗

October 31, 2025

Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for 2026.

Via Benzinga

Topics Earnings

Gilead GILD Q3 2025 Earnings Call Transcript ↗

October 31, 2025

Gilead GILD Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday? ↗

October 31, 2025

Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive.

Via Benzinga

GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds

October 31, 2025

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $7.77 billion. On the other hand, the...

Via StockStory

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)

October 31, 2025

From Gilead Sciences, Inc.

Via Business Wire

Meta Meltdown Sends Nasdaq Tumbling as Apple Shines After Hours ↗

October 31, 2025

Wall Street slipped on Thursday as disappointing results from Meta and cautious tones from the Fed weighed on sentiment. But after the closing bell, Apple’s record-breaking numbers helped restore a bit...

Via Chartmill

Topics Economy

Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares? ↗

October 31, 2025

Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?

Via The Motley Fool

Topics Regulatory Compliance

Gilead Sciences Inc (NASDAQ:GILD) Reports Mixed Q3 2025 Results with Strong Earnings Beat and Cautious Revenue Outlook ↗

October 30, 2025

Gilead Sciences Q3 2025 earnings beat EPS estimates with $2.47, but revenue outlook is cautious. HIV drug Biktarvy drives growth, while Veklury sales decline.

Via Chartmill

Topics Earnings

Gilead Sciences (NASDAQ:GILD) Exceeds Q3 Expectations

October 30, 2025

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) announced better-than-expected revenue in Q3 CY2025, with sales up 3% year on year to $7.77 billion. On the other hand, the company’s full-year...

Via StockStory

Covid Continues To Haunt Gilead. How One Drug Dinged Product Sales. ↗

October 30, 2025

Excluding the impact of Veklury, Gilead Sciences' product sales would have been closer to analysts' forecast.

Via Investor's Business Daily

Gilead Sciences Announces Third Quarter 2025 Financial Results

October 30, 2025

From Gilead Sciences, Inc.

Via Business Wire

Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗

October 30, 2025

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome...

Via Benzinga

Topics Economy

CVS Health Delivers Confident Outlook After Q3 Performance, Stock Hits 52-Week High ↗

October 29, 2025

CVS Health topped Q3 estimates with $102.9 billion in revenue and raised its 2025 EPS outlook to up to $6.65 amid strong segment growth.

Via Benzinga

A Glimpse of Gilead Sciences's Earnings Potential ↗

October 29, 2025

Via Benzinga

Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings

October 28, 2025

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results this Thursday after market close. Here’s what to expect.

Via StockStory

Topics Artificial Intelligence

Market's Perilous Peak: Is the U.S. Stock Market More Overvalued Than Ever?

October 27, 2025

New York, NY – October 27, 2025 – A chorus of concern is growing louder across financial markets, with prominent voices like MarketWatch raising alarm bells over what they describe as an unprecedented...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today ↗

October 27, 2025

Via Benzinga

Retail Investors' Top Stocks With Earnings This Week: SoFi, Apple, Meta And More ↗

October 27, 2025

Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites.

Via Benzinga

3 Value Stocks We Approach with Caution

October 27, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta

October 23, 2025

From Gilead Sciences, Inc.

Via Business Wire

Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence

October 22, 2025

San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the...

Via MarketMinute

Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts

October 19, 2025

The biotechnology sector is currently experiencing a significant surge in investor attention, characterized by a blend of cautious optimism and strategic focus. As of October 2025, this heightened...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

76 77 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.